Is OSTEOMYELITIS a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed OSTEOMYELITIS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 18 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported OSTEOMYELITIS to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and OSTEOMYELITIS. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause OSTEOMYELITIS, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes OSTEOMYELITIS. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if OSTEOMYELITIS ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing OSTEOMYELITIS: 18
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where OSTEOMYELITIS is a reported side effect: 0.5407%

FDA reports of any drug causing OSTEOMYELITIS : 13618
Average percentage for all medicated patients where OSTEOMYELITIS is reported as a complication: 0.0853%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with OSTEOMYELITIS:

FOSAMAX (10062 patients)
ZOMETA (5884 patients)
AREDIA (3752 patients)
ASPIRIN (1704 patients)
PREDNISONE (1605 patients)
COUMADIN (1106 patients)
DECADRON (1026 patients)
LASIX (998 patients)
OXYCONTIN (981 patients)
NEURONTIN (972 patients)
DEXAMETHASONE (970 patients)
AMBIEN (964 patients)
LIPITOR (905 patients)
PRILOSEC (900 patients)
CELEBREX (882 patients)
PERCOCET (869 patients)
NEXIUM (855 patients)
THALIDOMIDE (839 patients)
LEVAQUIN (808 patients)
ZOLOFT (803 patients)
SYNTHROID (798 patients)
VIOXX (792 patients)
PROTONIX (784 patients)
ATIVAN (777 patients)
TAXOTERE (770 patients)
LISINOPRIL (761 patients)
[THERAPY UNSPECIFIED] (749 patients)
VICODIN (702 patients)
FEMARA (682 patients)
CLINDAMYCIN (673 patients)
ACTONEL (642 patients)
ZOCOR (625 patients)
TAMOXIFEN CITRATE (614 patients)
ZOFRAN (613 patients)
FUROSEMIDE (592 patients)
METHOTREXATE (590 patients)
OXYCODONE HCL (584 patients)
MORPHINE (579 patients)
HYDROCHLOROTHIAZIDE (577 patients)
CHEMOTHERAPEUTICS NOS (574 patients)
PREVACID (573 patients)
PAXIL (566 patients)
FOLIC ACID (565 patients)
ARIMIDEX (561 patients)
ALBUTEROL (555 patients)
ATENOLOL (540 patients)
FOSAMAX PLUS D (536 patients)
AMOXICILLIN (535 patients)
PERIDEX (518 patients)
CALCIUM (516 patients)
DURAGESIC-100 (514 patients)
XANAX (512 patients)
ARANESP (504 patients)
NORVASC (492 patients)
ZANTAC (485 patients)
HERCEPTIN (485 patients)
CYTOXAN (472 patients)
TAXOL (466 patients)
VITAMIN D (464 patients)
XELODA (463 patients)
DILAUDID (460 patients)
ACETAMINOPHEN (453 patients)
VANCOMYCIN (448 patients)
POTASSIUM CHLORIDE (448 patients)
LORTAB (442 patients)
LORAZEPAM (442 patients)
GABAPENTIN (440 patients)
RADIATION THERAPY (436 patients)
REVLIMID (432 patients)
FLEXERIL (429 patients)
PREDNISOLONE (424 patients)
PREMARIN (420 patients)
CHLORHEXIDINE GLUCONATE (409 patients)
FASLODEX (398 patients)
IBUPROFEN (396 patients)
FLAGYL (395 patients)
COMPAZINE (394 patients)
REGLAN (389 patients)
ALLOPURINOL (386 patients)
LEXAPRO (385 patients)
PLAVIX (384 patients)
CYMBALTA (381 patients)
COLACE (381 patients)
AUGMENTIN '125' (380 patients)
LOVENOX (379 patients)
ZITHROMAX (374 patients)
MULTI-VITAMINS (374 patients)
TOPROL-XL (373 patients)
CIPROFLOXACIN (369 patients)
PROCRIT /00909301/ (363 patients)
AROMASIN (360 patients)
BONIVA (360 patients)
PREDNISONE TAB (358 patients)
EFFEXOR (352 patients)
PROZAC (351 patients)
LYRICA (351 patients)
FENTANYL (348 patients)
PEPCID (343 patients)
OMEPRAZOLE (342 patients)
ELAVIL (339 patients)
NAVELBINE (336 patients)
VELCADE (335 patients)
CEPHALEXIN (335 patients)
MORPHINE SULFATE (333 patients)
HUMIRA (330 patients)
VINCRISTINE (326 patients)
HYDROCODONE BITARTRATE (324 patients)
ADVAIR DISKUS 100/50 (324 patients)
SIMVASTATIN (323 patients)
KEFLEX (321 patients)
ADRIAMYCIN PFS (318 patients)
DIFLUCAN (318 patients)
ALENDRONATE SODIUM (308 patients)
CELEXA (307 patients)
ALPRAZOLAM (304 patients)
WELLBUTRIN (302 patients)
DIOVAN (301 patients)
LUPRON (301 patients)
WARFARIN SODIUM (299 patients)
AVELOX (297 patients)
CALCIUM CARBONATE (297 patients)
CALCIUM (UNSPECIFIED) (296 patients)
MS CONTIN (292 patients)
DIGOXIN (287 patients)
OXYCODONE (286 patients)
FLOMAX (285 patients)
REMICADE (284 patients)
CIPRO (281 patients)
PROMETHAZINE (281 patients)
VALIUM (280 patients)
ZYRTEC (276 patients)
FLUOROURACIL (272 patients)
GEMZAR (266 patients)
HEPARIN SODIUM INJECTION (266 patients)
LOPRESSOR (266 patients)
TYLENOL-500 (265 patients)
EPOGEN (263 patients)
COREG (262 patients)
CASODEX (260 patients)
PROCRIT (259 patients)
HYDROCODONE (259 patients)
NITROGLYCERIN (257 patients)
BACTRIM (256 patients)
MELPHALAN (251 patients)
LANTUS (251 patients)
HEPARIN (249 patients)
ALLEGRA (248 patients)
DARVOCET-N 100 (245 patients)
EVISTA (245 patients)
CLONAZEPAM (244 patients)
AVONEX (242 patients)
VITAMINS (UNSPECIFIED) (239 patients)
HORMONES (UNSPECIFIED) (237 patients)
FLONASE (234 patients)
CLARITIN (234 patients)
INSULIN (233 patients)
KLONOPIN (231 patients)
FLUCONAZOLE (230 patients)
SINGULAIR (229 patients)
MOBIC (224 patients)
ASCORBIC ACID (224 patients)
METOPROLOL TARTRATE (224 patients)
AVANDIA (223 patients)
NEUPOGEN (223 patients)
CORTICOSTEROIDS (UNSPECIFIED) (223 patients)
METRONIDAZOLE (221 patients)
ENBREL (221 patients)
TYLENOL (220 patients)
NYSTATIN (220 patients)
HYDROCORTISONE (220 patients)
ACYCLOVIR (216 patients)
FORTEO (216 patients)
COZAAR (214 patients)
ROCEPHIN (214 patients)
DIAZEPAM (214 patients)
GLUCOPHAGE (212 patients)
CYCLOPHOSPHAMIDE (208 patients)
DOXYCYCLINE (207 patients)
SKELAXIN (205 patients)
FERROUS SULFATE TAB (205 patients)
TYSABRI (204 patients)
PAMIDRONATE DISODIUM (202 patients)
RESTORIL (202 patients)
AVASTIN (199 patients)
CARBOPLATIN (198 patients)
PLAQUENIL (196 patients)
LIDOCAINE (193 patients)
STEROIDS NOS (193 patients)
LEVOTHYROXINE SODIUM (192 patients)
KLOR-CON (191 patients)
VITAMIN E (191 patients)
TRAZODONE HCL (191 patients)
PHENERGAN (190 patients)
METFORMIN HCL (187 patients)
ACTOS (186 patients)
ULTRAM (186 patients)
VITAMIN B6 (184 patients)
ZOLEDRONIC ACID (180 patients)
NAPROXEN (180 patients)
SPIRIVA (180 patients)
THALOMID (180 patients)
PREMPRO (179 patients)
METHADONE HCL (179 patients)
CRESTOR (179 patients)
AMITRIPTYLINE HCL (179 patients)
ZOLADEX (177 patients)
METOPROLOL (177 patients)
VALTREX (176 patients)
FAMOTIDINE (176 patients)
GLYBURIDE (175 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about OSTEOMYELITIS and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.